From pMDI Device to Therapeutic Effect

Pressurized metered dose inhalers, a critical solution for routine respiratory drug delivery, are currently the subject of considerable development activity. As manufacturers tackle the transition to low GWP (Global Warming Potential) propellants alongside evolving requirements for connected devices and lower cost medicines the need for more effective tools for pMDI formulation and reformulation intensifies.

This webinar showcases SmartTrack™, a novel integrated solution from Aptar Pharma that accelerates pMDI development. SmartTrack™ incorporates in vitro and in silico techniques that characterize every important process from pMDI actuation to drug delivery to the patient, and includes an alternative approach to comparative clinical endpoint for demonstrating bioequivalence. It can reduce time-to-market and program costs by accelerating new product development and regulatory decision-making.

Learn more from our experts about the challenges of reformulation with low GWP propellants, the value of using an integrated suite of tools to address them, and what SmartTrack™ can deliver. Case study data from the reformulation of a well-known API with a low GWP propellant are presented.